MedKoo Cat#: 525060 | Name: Firocoxib
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Firocoxib is a non-steroidal anti-inflammatory drug of the COX-2 inhibitor class, currently approved for use in dogs and horses. Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects.

Chemical Structure

Firocoxib
Firocoxib
CAS#189954-96-9

Theoretical Analysis

MedKoo Cat#: 525060

Name: Firocoxib

CAS#: 189954-96-9

Chemical Formula: C17H20O5S

Exact Mass: 336.1031

Molecular Weight: 336.40

Elemental Analysis: C, 60.70; H, 5.99; O, 23.78; S, 9.53

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 Weeks
100mg USD 450.00 2 Weeks
250mg USD 750.00 2 Weeks
500mg USD 1,250.00 2 Weeks
1g USD 1,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Firocoxib; Equioxx; Previcox; Librens; firocoxibum; ML 1785713; ML1785713; ML-1785713; NSC-758895; NSC758895; NSC 758895
IUPAC/Chemical Name
3-(Cyclopropylmethoxy)-4-(4-methylsulfonylphenyl)-5,5-dimethylfuranone
InChi Key
FULAPETWGIGNMT-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3
SMILES Code
CC1(C)C(C2=CC=C(S(=O)(C)=O)C=C2)=C(OCC3CC3)C(O1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 336.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Donnell JR, Frisbie DD. Use of firocoxib for the treatment of equine osteoarthritis. Vet Med (Auckl). 2014 Nov 4;5:159-168. doi: 10.2147/VMRR.S70207. PMID: 32670856; PMCID: PMC7337192. 2: Wagner SA, Fajt VR, Lo CP, Byrd CJ. Pharmacokinetics of oral firocoxib in un- weaned calves. J Vet Pharmacol Ther. 2021 Sep;44(5):793-798. doi: 10.1111/jvp.12971. Epub 2021 Apr 4. PMID: 33817876. 3: Latli B, Gao A, Kvaternick V, Tecle B, Pennino S, Yee NK, Song J. Synthesis of stable isotope-labelled firocoxib. J Labelled Comp Radiopharm. 2020 Jun 30;63(8):386-392. doi: 10.1002/jlcr.3842. Epub 2020 May 5. PMID: 32307719. 4: Brandi A, de Faria Lainetti P, Elias F, Rodrigues MMP, Fagundes Moraes L, Laufer-Amorim R, de Camargo LS, Salles Gomes COM, Fonseca-Alves CE. Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors. Animals (Basel). 2022 Dec 23;13(1):60. doi: 10.3390/ani13010060. PMID: 36611669; PMCID: PMC9817520. 5: Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses. Vet Anim Sci. 2023 Jan 11;19:100286. doi: 10.1016/j.vas.2023.100286. PMID: 36684818; PMCID: PMC9852958. 6: Kleinhenz MD, Odland C, Williams TE, Zhang Y, Fitzgerald AH, Sidhu PK, Wulf LW, Coetzee JF. Pharmacokinetics and tissue concentrations of firocoxib in sows following oral administration. J Vet Pharmacol Ther. 2020 Sep;43(5):491-498. doi: 10.1111/jvp.12864. Epub 2020 Apr 8. PMID: 32266983. 7: Phuwapattanachart P, Thengchaisri N. Analgesic efficacy of oral firocoxib in ovariohysterectomized cats. J Vet Sci. 2017 Jun 30;18(2):175-182. doi: 10.4142/jvs.2017.18.2.175. PMID: 27515266; PMCID: PMC5489464. 8: Rangel-Nava A, Ramírez-Uribe JM, Recillas-Morales S, Ibancovichi-Camarillo JA, Venebra-Muñoz A, Sánchez-Aparicio P. Pharmacological Regulation in the USA and Pharmacokinetics Parameters of Firocoxib, a Highly Selective Cox-2, by Pain Management in Horses. J Equine Vet Sci. 2019 Jun;77:36-42. doi: 10.1016/j.jevs.2019.02.007. Epub 2019 Feb 21. PMID: 31133314. 9: Stuart AK, KuKanich B, Caixeta LS, Coetzee JF, Barrell EA. Pharmacokinetics and bioavailability of oral firocoxib in adult, mixed-breed goats. J Vet Pharmacol Ther. 2019 Nov;42(6):640-646. doi: 10.1111/jvp.12795. Epub 2019 Aug 21. PMID: 31435966. 10: Bishop RC, Wilkins PA, Kemper AM, Stewart RM, McCoy AM. Effect of Firocoxib and Flunixin Meglumine on Large Colon Mural Thickness of Healthy Horses. J Equine Vet Sci. 2023 Jul;126:104562. doi: 10.1016/j.jevs.2023.104562. Epub 2023 May 11. PMID: 37172749. 11: Adhikari S, Tian J, Rustum AM. Comprehensive study on degradation profile of firocoxib and structural elucidation of its key degradation products. J Pharm Biomed Anal. 2023 Feb 5;224:115192. doi: 10.1016/j.jpba.2022.115192. Epub 2022 Nov 28. PMID: 36463770. 12: Coetzee JF, Sidhu PK, Seagen J, Schieber T, Kleinhenz K, Kleinhenz MD, Wulf LW, Cooper VL, Mazloom R, Jaberi-Douraki M, Lechtenberg K. Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. J Anim Sci. 2019 Jul 2;97(7):2750-2768. doi: 10.1093/jas/skz143. PMID: 31100113; PMCID: PMC6606487. 13: Stock ML, Gehring R, Barth LA, Wulf LW, Coetzee JF. Pharmacokinetics of firocoxib in preweaned calves after oral and intravenous administration. J Vet Pharmacol Ther. 2014 Oct;37(5):457-63. doi: 10.1111/jvp.12124. Epub 2014 Apr 8. PMID: 24708198. 14: Cook VL, Meyer CT, Campbell NB, Blikslager AT. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. Am J Vet Res. 2009 Aug;70(8):992-1000. doi: 10.2460/ajvr.70.8.992. PMID: 19645580. 15: Wang L, Rustum AM. Determination of Firocoxib and Its Related Substances in Bulk Drug Substance Batches of Firocoxib by a High-Speed Reversed-Phase HPLC Method With a Short Fused-Core Biphenyl Column. J Chromatogr Sci. 2022 Dec 5:bmac095. doi: 10.1093/chromsci/bmac095. Epub ahead of print. PMID: 36469498. 16: Friso AM, Segabinazzi LGTM, Cyrino M, Correal SB, Freitas-Dell'Aqua CP, Teoro do Carmo M, Dell'Aqua JA Jr, Miró J, Papa FO, Alvarenga MA. Periovulatory administration of firocoxib did not alter ovulation rates and mitigated post- breeding inflammatory response in mares. Theriogenology. 2019 Oct 15;138:24-30. doi: 10.1016/j.theriogenology.2019.06.045. Epub 2019 Jun 29. PMID: 31280182. 17: Araújo RA, Sales NAA, Basile RC, Feringer-Junior WH, Apparício M, Ferraz GC, Queiroz-Neto A. Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses. Vet Sci. 2023 Aug 22;10(9):531. doi: 10.3390/vetsci10090531. PMID: 37756053; PMCID: PMC10535825. 18: de Salazar Alcalá AG, Gioda L, Dehman A, Beugnet F. Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs. BMC Vet Res. 2019 Aug 29;15(1):309. doi: 10.1186/s12917-019-2052-0. Erratum in: BMC Vet Res. 2019 Oct 17;15(1):347. PMID: 31464629; PMCID: PMC6716846. 19: Letendre LT, Tessman RK, McClure SR, Kvaternick VJ, Fischer JB, Hanson PD. Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses. Am J Vet Res. 2008 Nov;69(11):1399-405. doi: 10.2460/ajvr.69.11.1399. PMID: 18980421. 20: Gardhouse S, Kleinhenz M, Hocker SE, Weeder M, Montgomery SR, Zhang Y, Porting A, Rooney T. Pharmacokinetics and ex vivo pharmacodynamics of oral firocoxib administration in New Zealand White rabbits (Oryctolagus cuniculus). Am J Vet Res. 2022 May 31;83(7):ajvr.21.11.0177. doi: 10.2460/ajvr.21.11.0177. PMID: 35930777.